Details

Povezanost fibroblastnega rastnega dejavnik 23 in signalne poti RANK/RANKL/OPG v kostnem tkivu pri bolnikih z osteoporozo : magistrski študij laboratorijska biomedicina
ID Žuran, Tina (Author), ID Marc, Janja (Mentor) More about this mentor... This link opens in a new window

URLURL - Presentation file, Visit http://www.ffa.uni-lj.si/fileadmin/datoteke/Knjiznica/magistrske/2011/Zuran_Tina_mag_nal_2011.pdf This link opens in a new window

Language:Slovenian
Keywords:kostna premena, fibroblastni rastni dejavnik 23, statistične metode, biokemijski kazalci, analiza kostnega tkiva
Work type:Master's thesis/paper
Typology:2.09 - Master's Thesis
Organization:FFA - Faculty of Pharmacy
Place of publishing:Ljubljana
Publisher:[T. Žuran]
Year:2011
Number of pages:62 f.
PID:20.500.12556/RUL-71289 This link opens in a new window
UDC:542:616.7(043.3)
COBISS.SI-ID:3080561 This link opens in a new window
Publication date in RUL:10.07.2015
Views:2310
Downloads:267
Metadata:XML DC-XML DC-RDF
:
ŽURAN, Tina, 2011, Povezanost fibroblastnega rastnega dejavnik 23 in signalne poti RANK/RANKL/OPG v kostnem tkivu pri bolnikih z osteoporozo : magistrski študij laboratorijska biomedicina [online]. Master’s thesis. Ljubljana : T. Žuran. [Accessed 6 April 2025]. Retrieved from: http://www.ffa.uni-lj.si/fileadmin/datoteke/Knjiznica/magistrske/2011/Zuran_Tina_mag_nal_2011.pdf
Copy citation
Share:Bookmark and Share

Secondary language

Language:English
Title:Association of the fibroblast growth factor 23 and RANK/RANKL/OPG signaling pathway in bone tissue in osteoporotic patients

Similar documents

Similar works from RUL:
  1. Vpliv farmacevtske industrije na politiko ZDA
  2. Ugled in uglednostni kapital v farmacevtski industriji v Sloveniji
Similar works from other Slovenian collections:
  1. Fotokemijska razgradnja imidakloprida v zemlji
  2. Toxic effects of selected neonicotinoids through different organisational levels
  3. Določanje parametrov kakovosti gelov za tuširanje
  4. Vpliv veziv na fizikalne lastnosti aktiviranih zeolitov
  5. Outsourcing v svetovni farmacevtski industriji

Back